Treatment with rm-IL-17A led to increased mRNA expression of key T cell chemokines such as CXCL9–CXCL11, adhesion molecules ICAM1 and VCAM1 and IL-17-dependent cytokines in melanoma cells. The gene discussed is CXCL9; the disease is melanoma.